Advances in research of perioperative immunotherapy for non-small cell lung cancer—advances in neoadjuvant immunotherapy
The treatment of non-small cell lung cancer(NSCLC)with a considerably high occurrence and lethality represents a significant global health challenge,which urgently needs to be addressed.With the introduction of immune checkpoint inhibitors(ICIs),new treatment avenues for NSCLC have emerged,showing significant survival benefits in patients with advanced NSCLC.In recent years,researchers have begun to explore the feasibility of incorporating ICIs into neoadjuvant therapy,finding that they also offer therapeutic benefits in this context.This article aims to review recent research progress on ICIs in the neoadjuvant treatment of NSCLC,focusing on their impact on patient survival,pathological response,and other aspects.These research findings shed light on new strategies and insights for improving the neoadjuvant treatment outcomes of NSCLC patients.
NETL
NSTL
万方数据
